Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Fig. 1

Mechanism of action by which tezepelumab improves clinical outcomes in patients with asthma. TSLP is released from the airway epithelium in response to insults such as virus, allergens and pollutants, triggering an inflammatory cascade. Tezepelumab blocks TSLP from binding to its heterodimeric receptor, thereby inhibiting the production of various inflammatory cytokines and cell types. The primary and secondary objectives of CASCADE comprise assessment of the effects of tezepelumab on the cell types labelled with an asterisk. IgE, immunoglobulin E; IL, interleukin; ILC2, group 2 innate lymphoid cell; Th, T helper cell; TSLP, thymic stromal lymphopoietin

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us